Cellnovo's Mobile Health Approach to Diabetes Care

Cellnovo is working smack at the intersection of two of the hottest areas in medtech: diabetes and mobile health. Aiming to be the iTunes of diabetes care, the firm hopes to transform today's piecemeal management of the disease. The private company has developed an integrated platform designed to ease the burden for patients with type 1 diabetes, their physicians and their families. Cellnovo's system integrates a blood glucose meter, an insulin pump, and a simple interface that makes it easy to gather and share among all interested parties the many parameters associated with diabetes care: diet, level and frequency of blood glucose readings, insulin delivery profiles, degree of physical activity, and health status, for example. Indeed, because success in type 1 diabetes care heavily depends upon the compliance and adherence of patients to numerous daily tasks as they try to live normal lives, the disease is a good test case for the first end-to-end, patient-centric solution.

Mary Stuart

Two of the highest priorities for innovation among both medical device and pharmaceutical companies are diabetes and mobile health. The...

More from Archive

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.